Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Understanding irAEs Is Vital for IO Combo Use in HCC
October 5th 2021In an interview with during the 2021 International Liver Cancer Association Annual Conference, David J. Pinato, MD discussed combination strategies in hepatocellular carcinoma, how to manage associated toxicities, and how safety profiles can help to inform treatment decisions for this patient population.
Read More
Determining the Efficacy of Neoadjuvant Cemiplimab in Hepatocellular Carcinoma
August 18th 2021Thomas Marron, MD, PhD an assistant professor of hematology and medical oncology at Mount Sinai Hospital, discusses the study design and key goals of adding perioperative cemiplimab, an anti-PD-1 antibody, to surgical resection for hepatocellular carcinoma.
Watch
Chinese Study Finds That Sintilimab and Biosimilar Bevacizumab Prolong HCC PFS
July 23rd 2021Sintilimab in combination with the bevacizumab biosimilar, IBI305, is associated with a significant overall survival and progression-free survival benefit over sorafenib in the first-line setting for the treatment of Chinese patients with unresectable, hepatitis B virus-associated hepatocellular carcinoma.
Read More
Clear Efficacy Benefit Not Shown With Atezolizumab/Bevacizumab Versus Lenvatinib in Unresectable HCC
July 19th 2021A network meta-analysis looking at 4 studies that assessed atezolizumab/bevacizumab compared to lenvatinib showed there was not a statistically significant improvement for patients with unresectable hepatocellular carcinoma.
Read More
Prospective Findings of TTFields/Sorafenib in Advanced HCC May Warrant a Randomized Study
July 16th 2021In an interview with Targeted Oncology, HEPANOVA EF-30 investigator, Eleni Gikka, MD, provided insight into the use of TTFields in combination with standard of care therapy for patients with advanced hepatocellular carcinoma.
Read More
Cabozantinib Plus Atezolizumab Reduces Risk of Disease Progression or Death in Advanced HCC
June 28th 2021The combination of cabozantinib and atezolizumab demonstrated improvement in both progression-free and overall survival compared with sorafenib, in patients with untreated advanced hepatocellular carcinoma.
Read More